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ABSTRACT
Introduction: Phototherapy has long been used for the treatment of inflammatory skin diseases, such
as psoriasis and atopic dermatitis. The most frequent treatment approach utilizes ultraviolet (UV) light,
however, recently, different lasers and low-level light therapies (LLLT) emitting wavelengths in the
spectrum of the visible light have also been tried for the treatment of inflammatory skin diseases with
variable success.
Areas covered: This review provides an update on the different forms of phototherapy used for the
treatment of psoriasis and atopic dermatitis. The proposed mechanism of action of the different
phototherapeutical approaches are covered, including the immunosuppressive effect of UV light, the
anti-inflammatory effect of vascular lasers and the LLLT induced photobiomodulation. The clinical
efficacy of the different treatment options is also discussed.
Expert opinion: Based on the efficacy and safety, NB-UVB represents the gold standard for treating
psoriasis and atopic dermatitis. The UVB excimer laser and excimer lamp might be the best option for
clearing localized therapy-resistant lesions. Home UV phototherapy systems might promote treatment
adherence and better compliance of the patients. Vascular lasers, IPLs and LLLT, however, can not
currently be recommended for the treatment of inflammatory skin diseases because of the lack of well-
controlled studies.
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Phototherapy is the use of ultraviolet (UV) radiation or visible
light for the treatment of different diseases. The roots of photo-
therapy can be traced back to 1500 BC when Hindus treated
vitiligo, an autoimmune skin disorder, with photosensitizing
plant extracts and subsequent sunlight exposure. For many cen-
turies only natural sunlight (heliotherapy) was used for the treat-
ment of different skin conditions, but even nowadays, it is still
highly popular for psoriasis and atopic dermatitis in many geo-
graphic areas in the World, especially in the Dead Sea [1]. As
heliotherapy is only feasible in certain periods of the year with
additional great dosing variables depending on the geographic
locations, artificial light sources have been developed to emit
selective wavelengths of the electromagnetic radiation.
Furthermore, the identification of photosensitizers from
plant extracts with unique photochemical properties resulted
in the development of the so-called photochemotherapeutic
approaches, that were for a long time the most effective
treatments for inflammatory skin diseases. Lasers and intense
pulse light (IPL) are well established therapeutical tools to
treat vascular congenital and acquired vascular lesions. As
one of the hallmarks of skin inflammation is the erythema,
targeting blood vessels with lasers or IPLs might be an alter-
native option to treat inflammatory skin diseases as well.
Indeed, in the last decades vascular lasers have been shown
to improve inflammatory skin diseases with variable success.
In recent years low-level light/laser treatments (LLLT) emitting
low-intensity visible light were tried for psoriasis and atopic
dermatitis, but their efficacy and the mechanism of action
need further clarification.
When selecting the appropriate treatment for the patients,
many different conditions, such as co-morbidities, age, and
disease severity has to be considered [2,3]. Although there
are many traditional agents and biological drugs for psoriasis
and atopic dermatitis, phototherapeutical approaches are still
widely utilized for the treatment of inflammatory skin diseases.
We performed a MEDLINE search via PubMed to review the
recent advances in phototherapy for psoriasis and atopic der-
matitis, and the most interesting papers based on the Expert’s
selection were used for this review.
2. Phototherapeutical approaches
2.1. Common pathogenetic factors in immune-mediated
skin diseases
Although psoriasis and atopic dermatitis are clinically, histolo-
gically, and immunologically distinct diseases, both are char-
acterized by activated T-cell infiltration in the skin that is
followed by increased proliferation of keratinocytes resulting
in the thickening of the skin. These T-cell mediated diseases
differ in skin-infiltrating T-cell subpopulations [4]. In psoriasis,
Th17, Th22 cells and type 3 innate lymphoid cells play a crucial
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role in producing IL-17 and IL-22 and TNFα, whereas IL-23 is
the key cytokine responsible for Th17 activation. Th1 cell-
derived interferon-gamma (IFN-γ) is also elevated in psoriatic
skin. In contrast, atopic dermatitis is characterized by the
accumulation of Th2 cells, and their respective cytokine milieu
IL-4, IL-13, and IL-31. In chronic atopic dermatitis lesions, Th1
cells-derived IFN-γ and Th22 cells-produced IL-22 might also
have relevance [4].
2.2. UV-induced immunosuppression
Although there are Differences in the activated lymphocyte
populations in psoriasis and atopic dermatitis, both topical
(tacrolimus, pimecrolimus) and systemic (cyclosporine) immu-
nosuppressive treatment approaches are highly effective for
the treatment of these immune-mediated skin diseases. These
immunosuppressive drugs exert their effect by inhibiting cal-
cineurin, thereby suppressing activated T cells, independently
on the subpopulation involved in the disease. The high effi-
cacy of immunosuppressive treatments suggests that target-
ing T cells might be a common therapeutical approach for
psoriasis and atopic dermatitis.
Ultraviolet light from the sun or artificial light sources exert
a profound immunosuppressive effect, that is mediated – at
least partly – by inducing apoptotic cell death in activated
T cells. The immunosuppressive effects of the UV light in the
skin depend on many different variables, such as the wave-
lengths, the radiation intensity and the treatment dose, the
number of treatment sessions and on the optics of the human
skin. Ultraviolet radiation can be classified to as UVB radiation,
emitting wavelengths in between 280–320 nm, and UVA radia-
tion that contains wavelengths in between 320–400 nm. In
general, UVB light has a more profound immunosuppressive
effect than UVA light. Psoralen plus UVA light (PUVA) is a form
of photochemotherapy. Psoralens are small molecules, that
enter cells and intercalate DNA. Esposure of cells to UVA
light results in covalent binding of psoralens to the DNA,
thereby blocks the proliferion of the cells, and modify their
gene expression profile [5].
The most commonly used phototherapeutical devices that are
in use today are broadband UVB (BB-UVB), narrowband UVB (NB-
UVB), xenon chloride (XeCl) excimer laser and lamp, UVA1, and
UVA for psoralen photochemotherapy (PUVA) (Table 1). The dif-
ferent UV wavelengths have distinct photochemical and photo-
biological properties, including differences in penetration depth
and themolecules in the skin withwhich they interact (Table 2). As
a consequence, different UV light sources have unique properties
regarding potency, side effects, and diseases in which they are
effective. In general, the shorter UVB wavelengths have more
powerful biological effects in vitro, however, in vivo the wave-
lengths below 300 nm are absorbed in the upper layer of the skin,
resulting in shorter penetration depth. Wavelengths below
300 nm are clinically less effective but more inflammatory.
Therefore, broadband UVB (BB-UVB) has been replaced by light
sources filtering out wavelengths below 300 nm, such as in selec-
tive UV phototherapy (SUP) devices, that emit wavelengthsmainly
in between 300–320 nm. Determination of the optimal wave-
lengths in psoriasis resulted in the development of the narrow-
band UVB (NB-UVB) lamp, that is nowadays the most frequently
used treatment option for inflammatory skin diseases. The mono-
chromatic 308 nm excimer laser and excimer lamp might be
regarded as super narrow-band high-intensity UVB light sources,
that are the best options for targeted phototherapy [6]. Recently
UV light emitting diode (UV-LED) delivering high-intensity UV light
in 300–312 nm wavelength, and a flat-type fluorescent UVB
(F-UVB) lamps emitting UVB in the 311–313 nm range were devel-
oped, that might provide novel options for targeted UV therapy
[7,8]. The longer UV wavelengths of 320–400 nm (UVA) are biolo-
gically less active and are used only for the treatment of mild
atopic dermatitis. However, high-intensity UVA1, emitting wave-
lengths in between 340–400 nm, is highly effective for acute
atopic dermatitis.
Article Highlights
● UVB is a highly effective and safe treatment for psoriasis and atopic
dermatitis
● Immunosuppression is the main mechanism of action of UV light
● Treatment with excimer lasers/lamps is an excellent new option for
localized lesions
● Home UV phototherapy might represent a good alternative for office-
based procedures
● The efficacy of vascular lasers, IPLs, and LLLT for psoriasis and atopic
dermatitis are not convincing yet.
Table 1. Phototherapeutical approaches for the treatment of psoriasis and
atopic dermatitis.
Phototherapeutical method Abbreviation Spectrum (nm)
Natural phototherapy (heliotherapy) SOLAR UV 290–3200
Broadband UVB BB-UVB 290–320
Narrowband UVB NB-UVB 311–313
Selective UV phototherapy SUP 300–330
Xenon chloride excimer laser XeCl laser 308
Xenon chloride excimer lamp MEL 308
UVB light emitting diode UVB-LED 310–312
Flat-type fluorescent UVB lamp F-UVB 311–313
UVA UVA 320–400
Mixed UVB/UVA UVAB 300–400
Psoralen + UVA photochemotherapy PUVA 320–400
UVA-1 phototherapy UVA-1 340–400
Pulsed Dye laser PDL 585/595
Nd: YAG laser Nd: YAG 1064
Intense pulse light IPL 535–1250/535–575
Low-level laser therapy LLLT 400–500, 630–800
Table 2. Mechanism of action of UV phototherapy.
UV light-proposed effects References
TARGET CELLS Apoptosis induction in T cells [28–31,39]
Apoptosis induction in keratinocytes [32]
Induction of regulatory T- cells [33–35,41–43]
Inhibition of NK cell function [37]
Improvement of the disturbed
vasculature
[27]
Inhibition of Langerhans cells and
macrophages
[21,36]








Induction of cytoplasmic transcription
factors
[21–24]
Modulation of cytokine production [39–43]
1206 L. KEMÉNY ET AL.
2.3. Targeting blood vessels
A hallmark of psoriatic skin is the remarkable transformation of the
local microvascular system [9]. Pinpoint bleeding on the surface of
psoriatic plaques after removing the scales (Aspitz sign) is
a characteristic clinical phenomenon of psoriasis, that is due to
regularly distributed dilated capillaries, and numerous, enlarged,
superficialized dermal papillae containing dilated/tortuous capil-
lary loops [10,11]. The increased dermal microvasculature facili-
tates the trafficking of leukocytes from the circulation into the skin
and therefore plays an essential role in the development and
maintaining inflammation in psoriasis [12]. Therefore, inhibition
of leukocyte trafficking via selective destruction of the dilated
capillariesmaybe an effective therapeutic intervention in psoriasis.
Although the role of blood vessels and microcirculation in
atopic dermatitis has not been extensively studied yet, similarly
to other chronic inflammatory skin conditions, increased angio-
genesis has also been suggested to be involved in the pathogen-
esis of atopic dermatitis [13]. Therefore, targeting blood vessels
might have therapeutic potential also in atopic dermatitis.
Congenital and acquired vascular lesions are treated with
lasers with high efficacy. Among the various lasers used for
treating vascular lesions, pulsed dye laser (PDL) emitting
585 nm or 595 nm monochromatic light, have the best effi-
cacy in localized psoriasis [14,15], but also in localized lesions
in atopic dermatitis [16]. There are also some reports on the
use of Nd: YAG laser with emission in 1064 nm for psoriasis
[17]. Intense pulsed light (IPL) devices produce flashes of light
with high energy levels, with emitted wavelengths range of
usually 400 nm to 1200 nm and the lower wavelengths can be
eliminated by the various cut off filters, which usually range
from 755–1000 nm. Therefore, targeting blood vessels by IPLs
might also be a treatment option for psoriasis [18] but also for
the reduction of facial redness in atopic dermatitis [19].
2.4. Photobiomodulation?
To avoid UV-induced increased risk of skin carcinogenesis, UV-free,
low-intensity light sources have been developed for the treatment
of psoriasis and atopic dermatitis. These low-level light therapies
include light emitting diodes (LEDs) operating in different wave-
lengths usually in between 400–500 nm (blue light), and in 630–-
770 nm (red light), and up to 830 nm (near-infrared), but there are
also many low-intensity lasers operating in these wavelengths,
such as the Helium-Neon laser (He-Ne 632.5 nm). LLLT has been
shown to exert a „photobiomodulation” effects, by targeting dif-
ferent cells types and intracellular structures, but their exact
mechanismof action is not known. Basedon the high safety profile
and the relatively low price of the LLLT devices, in recent years the
LLLT treatments became popular for the treatment of many
inflammatory skin conditions including psoriasis and atopic
dermatitis.
3. Mechanism of action of phototherapy
3.1. UV phototherapy
UV phototherapy works through local rather than systemic
effects, therefore without the side effect of profound systemic
immunosuppression. This explains why it has still kept its
place in the dermatologist’s arsenal even nowadays, in the
era of the revolutionary novel biological agents.
UV radiation (UVR) exerts a multitude of biological effects
within the skin (Figure 1), different researches have already
revealed many of them throughout the century, but still, it
remains unclear which of these induce clearance of the
lesions [20]. In general, the effects of UV radiation can be
divided into two groups: immediate and delayed effects.
The immediate effects, such as membrane and DNA
damage, induction of cytoplasmatic transcriptional factors
and isomerization of chromophores (such as urocanic acid)
have been known since 1967 [21], these induce instantly
growth arrest and apoptosis [21].
There is a direct change of molecular structure in DNA due to
photon absorption after UVB which inhibits the DNA transcription
machinery and causes cell cycle arrest in human fibroblasts and
epidermal cells (phototype I reaction) [22,23]. In the case of photo-
chemotherapy, when the skin is treated with a photosensitizing
Figure 1. Mechanism of action of ultraviolet radiation in treating immune-mediated skin diseases.
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drug (psoralen) subsequently followed by UVA radiation, the inter-
action of photon-excited aromatic molecules with molecular oxy-
gen generates reactive oxygen species, which cause many
alterations in the cells, such as DNA damage, cell membrane
damage via lipid peroxidation and interaction with signaling path-
ways (phototype II reaction) [24–26].
The short-term effects are reversed 48 to 72 hours after
irradiation, as the DNA repair starts within an hour after
irradiaton, and the cells start then to proliferate again. UV
radiation has the ability to reverse the skin’s disturbed
vessel architecture as well, therefore in psoriatic lesions it
normalizes the characteristical elongated capillary loops
[27]. Delayed effects of UV radiation include the inhibition
of both the adaptive and innate immune cells that results
in immunosuppression.
Among the diverse effects on inflammatory cells, apoptosis
induction in epidermal and dermal T cells seem to be the most
important mechanism of action of UV radiation induced
immunosuppression [28–31]. Although keratinocytes are
more resistant to UV radiation compared to that of T cells,
UVB induced apoptosis in keratinocytes also plays a key role in
the clearance of psoriatic plaques [32]. Furthermore, UV-B and
PUVA activate T regulatory (Treg) cells, and stimulation of
Tregs results in the downregulation the overreactive immune
response in psoriasis [33–35].
UV radiation affects antigen presenting cells as well. After 7
UV treatment sessions the number of Langerhans cells
decreases by 90%, which alters the deviated antigen presenta-
tion [21]. Furthermore, the photo-oxidative stress causes
cytoskeleton damage in the remaining dendritic cells, which
inhibits the further stimulation of T-cells. Cytokine secretion, as
well as the number of macrophages, were also diminished by
UV radiation [36]. Through the action of the reactive oxygen
species UV light switches off the activity of neutrophils and
inhibits the NK cell function as well [37,38].
These cellular effects are accompanied by altering the
cytokine milieu, the suppression of inflammatory cytokines
IL-2, IL-8, IL-9, IL-17, IL-22 and IL-23, TNF-a and IFN-g, and
induction of the immunosuppressive cytokine IL-10 also con-
tributes to the cessation of the inflammation [39–43].
3.2. Vascular lasers and IPLs
The effect of vascular lasers such as PDL or long pulsed Nd: YAG or
IPLs is based on the selective absorption of light by oxyhemoglo-
bin inducing photothermolysis of capillaries without causing
damage to other skin structures [44]. The exact mechanism of
action of PDL in psoriasis was investigated in detail by Racz et al.
[15]. They found that PDL treatment reduced the expression of
VEGFR2 and VEGFR3 mRNA as early as 3 hours, whereas E-selectin
expression was significantly reduced 24 hours after one single
treatment. Interestingly, there was also a decreasing trend in the
expression of IL-23p19 mRNA by PDL treatment. Long-term PDL
treatment resulted in the decreased expression of TNF-α and IL-
23p19, and reduced β-defensin 2, keratin 17 and Bcl2. The
decreased expression of the endothelial molecules VEGFR2 and
E-selectin corresponds with the proposed primary target of the
PDL. Furthermore, the decreased expression of VEGFR3 early after
PDL treatment may also contribute to its efficacy in psoriasis.
These results suggest that selective targeting of blood vessels by
PDL results in relevant biological changes in psoriatic plaques,
calling attention to the role of blood vessels, as a previously less
recognized target option in psoriasis.
3.3. Low-level light/laser therapy
The biological effect of low-intensity visible light/laser in the skin is
not exactly clarified yet. The different wavelengths (400–800 nm),
differences in intensity and penetration depth might result in
contradictory data concerning the observed biological effects. In
the blue range (400–500 nm), porphyrin-containing enzymes and
flavoproteins are supposed to be the photoacceptors linking the
mitochondrial respiratory chain to photostimulation [45–47]. In
the visible-to-near-infrared spectral range, the cytochrome
c oxidase might be the photoacceptor [48]. Red light at 660 nm
exerts a so-called photobiostimulatory effect by producing oxygen
radicals and inducing the proliferation of lymphocytes [49].
Liebmann investigated a panel of LEDs with distinct wavelengths
ranging from near-UV to infrared (412–940 nm) in order to define
wavelength-specific biological effects on cultured human skin
cells [50]. They found that irradiation with wavelengths between
630 and 940 nm did not affect cell proliferation. Irradiation with
wavelengths of 412, 419, and 426 nm at high fluences (66–100 J/
cm2) and 453 nm wavelength at very high fluences (4500 J/cm2)
was cytotoxic for skin-derived endothelial cells as well as for
keratinocytes. However, irradiation with nontoxic fluences
reduced the proliferation of both endothelial cells and keratino-
cytes by inducing differentiation [50]. These in vitro data might be
relevant for LLLT therapy in patients with immune-mediated
hyperproliferative skin diseases such as psoriasis or atopic
dermatitis.
4. Clinical efficacy of phototherapy in psoriasis
4.1. UV light based treatments
4.1.1. Action spectrum of UV light in treating psoriasis: the
traditional belief
UVB light (280–320 nm) is the most frequently used wave-
length for the therapy of psoriasis, and there are a high num-
ber of UV devices on the market. It is an important and
clinically relevant question, which UV light sources are the
most effective in treating psoriasis. Interestingly, there is only
one study addressing this question, when Parrish and
Jaenecke irradiated psoriatic plaques with different wave-
lengths using a monochromator [51]. They found that wave-
lengths below 300 nm were erythematogenic, but
therapeutically not effective, whereas wavelength at 313 nm
was less erythematogenic and at the same time was highly
effective in improving the patients’ skin lesions. These results
served as the basis for the development of NB-UVB lamp, that
is nowadays the most frequently used phototherapeutical
option. Indeed, most of the clinical studies showed that NB-
UVB produced a superior clinical and histopathological resolu-
tion of moderate-to-severe psoriasis in patients compared
with BB-UVB when used in suberythematogenic dosis [52].
However, in another randomized trial, the efficacies of the BB-
UVB and NB-UVB light in treating psoriasis were compared,
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and no difference was found between those treated with the
two methods in terms of the median number of treatments to
clear, proportions of patients achieving clearance and
improvement in psoriasis severity scores [53]. These contra-
dictory data suggest the necessity of the revision of the action
spectrum of UVB for treating psoriasis published more than
35 years ago. The comparison of the therapeutical efficacies of
the different UVB light sources in treating psoriasis is extre-
mely difficult. The different variables (spectrum, irradiation
dose, intesity, disease characteristics) will influence the ther-
apeutical effect. Therefore, the general belief that NB-UVB is
more effective than BB-UVB light might be questioned.
4.1.2. Action spectrum of UV light in treating psoriasis:
a new model
One of the major mechanisms of action of UVB light in the
treatment of inflammatory dermatoses seems to be
a cytotoxic effect on epidermal T cells, where the mechanism
of cell death is most probably apoptosis [28]. Earlier, in
a bilateral comparison study, NB-UVB cleared the psoriatic
plaques more effectively and was a more potent inductor of
T cell apoptosis than BB-UVB; therefore, the T cell apoptosis-
inducing capacity of a UVB light source could be reflected by
its clinical efficacy [29]. We also found that the Xenon chloride
UVB laser was more effective in treating psoriasis and in indu-
cing T cell apoptosis than NB-UVB [30]. Later, using polychro-
matic UV light sources, the wavelength dependence of UVB
light for the induction of T cell apoptosis was also determined.
The regression line of the action spectrum demonstrated
a continuous decrease from 290 nm to 313 nm [31].
As the extent of T cell apoptosis induction and the penetration
of UVB light into the dermis is wavelength-dependent, the wave-
length spectrum of optimal dermato-phototherapymight depend
on the thickness of the skin lesion. We computed the theoretical
action spectrum of UVB for the induction of intraepidermal T cell
apoptosis. The formula created by Bruls et al. (1984) [54] was
modified to compute the theoretical wavelength dependence of
intraepidermal T cell apoptosis as a function of epidermal thick-
ness. As thepathognomic T cells in psoriasis are localized along the
dermo-epidermal junction and in the epidermis, we computed
how the thickness of epidermis has to be transmitted by the UVB
radiation to reach these intraepidermal The thickness of psoriatic
human epidermis from the lower forearm is 180–360 μm depend-
ing on the extent of acanthosis [55]. In another work, the suprapa-
pillar part of the stratumMalpighi seemed to be constantly 43 μm
thick, while the thickness of the rete pegs of the stratum Malpighi
increased as the degree of acanthosis increased (160–420 μm) [56].
In line with these observations, disease-mediating T cells are loca-
lized at 65–460 μm from the surface of the skin, depending on the
degree of acanthosis. Using these data, we calculated the theore-
tical extent of intraepidermal T cell apoptosis induction in the
range 290–313 nm depending on the epidermal thickness of the
irradiated skin. For T cells located at 65 μm and 250 μm from the
surface, 302 nm and 313 nm seem to be the most efficient wave-
lengths, respectively. For T cells localized from approximately
140 μm from the skin surface, the wavelengths 302–313 nm are
equally efficient in inducing apoptosis. Figure 2 depicts these three
theoretical action spectra.
The spectral distribution of a UVB light source influences the
clinical results by having an effect on the apoptosis induction
capacity and having an influence on the absorbance and trans-
mittance of the light in the epidermis [57]. Although shorter
wavelengths seem to induce T cell apoptosis more efficiently;
on the other hand longer wavelengths penetrate better into
the epidermis. In our opinion, plaque thickness is to be con-
sidered an important factor determining optimal phototherapy.
Figure 2. Action spectrum of ultraviolet B (UVB) to induce intraepidermal T cell apoptosis.
The efficacy of different UVB wavelengths to induce intraepidermal apoptosis in case of (a) thin epidermis (d = 65 um from the surface of the skin), (b) moderately acanthotic epidermis
(d = 140 um from the surface of the skin), or (c) severily acanthotic epidermis (d = 250 um from the skin surface). AIie is the theoretical extent of intraepidermal T cell apoptosis induction
computed by multiplying the extent of in vitro T cell apoptosis induction and the percentage of transmitted UVB light at each wavelength studied, plotted on a relative scale.
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Gerber et al. (2003) [58] proposed a UVB excimer laser treat-
ment using dosages that depend only on plaque erythema and
ont he determination of epidermal thickness using ultrasound.
They found a correlation between the induction of erythema
and the epidermal thickness of the plaque. With the introduc-
tion of their phototherapeutic regimen, based on individual
plaque thickness, the cumulative doses needed to achieve
complete clearance were reduced by 40%.
Although UV induced T cell apoptosis is not the only
mechanism underlying the efficacy of UVB phototherapy [59],
we propose that plaque thickness is a major contributor to the
success of UVB phototherapy. Based on our data, longer wave-
length UVB phototherapy would be ideal for the treatment of
thick psoriatic plaques, while short-wavelength UVB radiation
would be optimal for the treatment of thin skin lesions. Further
clinical studies are needed to address this question in a clinical
setting.
4.1.3. UV phototherapy in the clinical practice
UV phototherapy represents a safe and highly effective treat-
ment option for psoriasis. Nowadays, NB-UVB is the most com-
monly used phototherapeutical approach and can be regarded
as the gold-standard in phototherapy for moderate to severe
psoriasis [60–62]. Although UV light was recently classified as
a carcinogen, broad-band UVB and narrow-band UVB have not
yet been linked to cutaneous carcinogenesis when treating psor-
iasis. However, PUVA increases the risk for squamous cell carci-
noma of the skin, especially after following 350 or more
phototherapy sessions over a lifetime [63]. Therefore, PUVA is
a less and less frequently used treatment option [60].
For mild psoriasis, affecting less than 10% of the body surface
area, that do not respond well to conventional topical treatments,
the targeted, localized therapy using XeCl excimer laser or the
excimer lamp seems to be the best treatment approach [60].
These lasers and lamps emit monochromatic radiation with
a wavelength of 308 nm, that is just in the middle of the antipsor-
iatic spectrum. Moreover, using of excimer laser in treating thick,
therapy-resistant lesions has the additional benefit of leaving the
clinically uninvolved, healthy skin protected from UV, allowing
high-intensity UV radiation to be delivered to the involved plaques
that results in fast therapeutic response [6,64–66]. As the 308 nm
excimer laser is expensive, and the maintenance costs are also
high, cheaper monochromatic excimer lamps have been devel-
oped. As there are no differences in the clinical efficacies in
between the coherent 308 nm excimer lasers and the non-
coherent 308 nm excimer lamps [67], in most of the clinics the
excimer lamps are nowadays used for the treatment of localized
psoriasis.
Office-based phototherapeutical approaches are highly
effective, but the treatments are time-consuming and incon-
venient. To overcome these difficulties, home phototherapeu-
tical approaches represent a good alternative for the
treatment of inflammatory skin diseases. Home UVB treat-
ments include whole-body and portable handheld units for
targeted phototherapy. Because of its excellent safety profile,
NB-UVB is generally recommended for home phototherapy.
Great number of studies showed that home UVB photother-
apy is safe and comparable efficacious as office-based treat-
ment [68,69]. Although formal prescriptions are not required,
before starting a home-phototherapy regime, dermatologists
should determine the dosing schedule, duration of treatment
and how to address the potential side effects. Recently
a lightweight, handheld UVB-LED has been developed for
home phototherapy. This LED device with a smartphone appli-
cation, a secure server with data storage, and a physician web
portal might represent a highly precise modality for home
phototherapy. Phototherapy administration guided by the
smartphone application resulted in high patient’s compliance
and satisfaction [70]. Theoretically, tanning beds could also
represent a convenient way to obtain UV exposure when
office phototherapy is not feasible. Indeed, about half of psor-
iasis patients report using tanning beds, and most of them
noted improvement [71]. However, the wavelengths of UVA
and UVB irradiation from tanning beds are poorly defined;
they tend to emit primarily UVA irradiation. Therefore, recom-
mending the use of tanning beds as a potential treatment
should be carefully justified [69]. One of the physicians major
fear of recommending self-administered home phototherapy
is the overuse of the phototherapy units. With the improve-
ment of knowledge of the physicians about home photother-
apy and with careful patient selection, self-administered
phototherapy could be a satisfactory option for psoriasis
patients. Moreover, home phototherapy could also reduce
the economic burden of health care institutes.
4.2. Vascular lasers and IPL
Although targeting blood vessels by PDL and Nd: YAG lasers, or
with IPLs systems seem to be good alternatives for the 308 nm
excimer lasers/lamps to treat localized psoriatic plaques, vascular
lasers are not frequently used in the clinical practice to treat
psoriasis due to their high cost and lack of reimbursement.
However, probably because of the insufficient well-controlled
clinical data on the efficacy, the use of vascular lasers and IPLs
are not mentioned for the treatment in the psoriasis guidelines.
However, clinial data suggest the efficacy for PDL, as several
studies reported that psoriatic plaques were partly or completely
cleared by PDL treatment [72–76]. However, PDL might serve an
alternative option for difficult-to-treat areas, such as for palmo-
plantar psoriasis [77], or nail psoriasis [78]. As treatment of iso-
lated nail psoriasis is extremely difficult, new data on the efficacy
of Nd: YAG laser or IPL in these special clinical conditions might
be of clinical interest [17,18].
4.3. Low-level laser/light therapy (LLLT)
Recent attempts to use UV free devices for the treatment of
inflammatory skin diseases resulted in the development of UV-
free light sources emitting blue (400–500 nm) or red (600–-
800 nm) light. The clinical results using LLLT for psoriasis are,
however, inconsistent. Blue light treatment of selected psor-
iatic plaques three times weekly for four weeks did not result
in any clinical improvement compared to untreated plaques
[79]. On the other hand, in another study using higher irradia-
tion dosages, blue as well as red light, three times weekly for
four consecutive weeks, induced improvement of psoriasis
[80]. This clinical improvement was identical for both light
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sources. However, in this clinical study, there were no control,
non-irradiated (or sham-irradiated) plaques, and 10% salicylic
acid was allowed to use throughout the clinical trial. Therefore
the interpretation of the results is difficult because just the
removal of the scales by salicylic acid might result in a 30%
improvement of a single psoriatic lesion. On the other hand, in
a prospective, randomized study, the UV-free blue light treat-
ment improved the psoriatic plaques significantly compared
to nontreated lesions [81]. Because of the safety of the UV-free
phototherapy, this approach was designed for home treat-
ment. Treatment barrier might be the lengths of the treat-
ment, as irradiation of one single plaque in this study took
30 minutes, and the treatment was performed 5–7 times
a week in the first four weeks, and three treatments for eight
weeks. Although the safety is without any doubt is important
in phototherapy, due to the conflicting results and the
observed the low efficacy obtained with LLLT, further clinical
trials are necessary before suggesting the use of LLLT for the
treatment of psoriasis.
5. Clinical efficacy of phototherapy for atopic
dermatitis
5.1. UV light based treatments
UV light based treatment is well documented and frequently
used for mild to moderate atopic dermatitis. There are many
treatment guidelines and systematic reviews on the use of the
different UV light sources in atopic dermatitis [82–84]. Natural
sunlight, BB-UVB, NB-UVB, UVB excimer laser, UVAB, UVA,
UVA1, topical, and systemic psoralen plus UVA (PUVA) have
all been shown to improve the clinical symptoms [85].
Although the comparison of the different therapeutical
approaches is as difficult as in psoriasis, clinical trials suggest
that NB-UVB is superior in clearing atopic dermatitis compared
to BB-UVB or UVA1 [86,87].
Currently, the most commonly used or UV phototherapy in
Europe is NB-UVB and UVA1, where NB-UVB may be preferred
in chronic lesions and UVA1 for acute flares [84]. Although
308 nm UVB excimer laser might be a new treatment option
for localized, therapy-resistant plaques [88], the recent
European guideline does not recommend its use because of
the limited number of reports [84]. All UV treatments, espe-
cially PUVA, pose a long-term risk of development of skin
cancer. Therefore careful evaluation is necessary before initiat-
ing any UV phototherapy, especially PUVA treatment. Anyway,
NB-UVB is generally the most commonly recommended
phototherapeutical approach considering its low-risk profile,
relative efficacy, and availability.
5.2. Vascular lasers and IPL
As there were some reports on the efficacy of vascular lasers in
psoriasis, the efficacy of PDL was also tested in atopic derma-
titis. In a pilot study, PDL treatment was effective in treating
small areas of chronic localized eczema [16]. IPL treatment also
reduced the facial redness caused by atopic dermatitis [19].
However, the data until now are sparse, therefore currently
PDL and IPL are not recommended for the treatment of atopic
dermatitis [84].
5.3. Low-level laser/light therapy (LLLT)
As conventional UV irradiation bears the risk of developing
skin cancer and promotes accelerated skin aging, attempts
have been made to develop UV-free devices for the treatment
of skin diseases. There are only a few reports on the efficacy of
UV-free blue light irradiation in atopic dermatitis. Previously,
blue light at wavelengths between 400 and 495 nm improved
itch and skin lesions in patients with atopic dermatitis [89].
Full-body blue light irradiation was also effective in reducing
the clinical symptoms of the patients [90]. However, in this
clinical trial, the blue light was used as an „add on” therapy,
patients could use topical corticosteroids as well. Therefore
the results are not easy to interpret. The targeted, local UV-
free blue light treatment was also found to improve the
clinical symptoms in a small, randomized study [91].
Recently, a randomized controlled trial has been initiated
using the full-body blue light device for the treatment of
atopic dermatitis [92]. The results of this ongoing clinical
study might answer the question whether blue light might
be added to our therapeutical arsenal to treat atopic derma-
titis. However, given the limited number and quality of
reports, currently, the European guideline does not recom-
mend LLLT for the treatment of atopic dermatitis [84].
6. Expert commentary
Based on the clinical observation that sunlight improves
a great number of inflammatory skin conditions, different
artificial UV light sources have been developed in the early
20th century for the treatment of skin diseases. Various
attempts have been made to elucidate the exact mechanism
of action and the clinically most adventurous wavelengths.
Initially, BB-UVB light sources were utilized that emit wave-
lengths throughout the whole UVB spectrum. Action spectrum
studies suggested that wavelengths between 304 and 313 nm
were clinically most effective to clear psoriatic lesions [51].
These findings lead to the development of the NB-UVB light
sources in the 1980s. We introduced the 308 nm excimer laser
technology to treat mild to moderate psoriasis in 1996 [6]. This
innovation opened a new way for the development of other
targeted phototherapeutical approaches, such as for excimer
lamps and UVB-LED devices. As office-based UV phototherapy
is time-consuming, innovation in home UV phototherapy sys-
tems implementing a smartphone application and web-based
portal might promote adherence and better care for the
patients [70].
Although UB phototherapy is a safe and cost-effective treat-
ment for psoriasis and atopic dermatitis, previous data have
shownd a decrease in the use of phototherapy [93]. However,
a recent analysis based on the Healthcare Common Procedure
Coding System (HCPCS) codes revealed that the overall volume
of phototherapy services billed to Medicare from 2000 to 2015
increased annually by 5% in the US. The most commonly used
phototherapy was the UVB comprising 77% of all phototherapy
services. While there was a 9% decline in PUVA therapy, the
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excimer laser services grew by 29% annually [94]. These data
suggest that even in the era of highly effective biologics, UV
phototherapy represent an important therapeutic tool in derma-
tology. However, vascular lasers, IPLs, and LLLT cannot currently
be recommended for the treatment of inflammatory skin dis-
eases until more, well-controlled studies confirm their efficacy.
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